Hantong Medical secures tens of millions in Pre-A+ funding to advance its HawkSonic Renal Artery Ultrasound Ablation System, targeting the growing hypertension market in China.

Information on the Target

Shanghai Hantong Medical Technology Co., Ltd. (referred to as "Hantong Medical") has successfully completed a Pre-A+ round of financing, raising tens of millions of yuan. This funding will primarily support the clinical research and development of its core product—the Renal Artery Ultrasound Ablation System. Hantong Medical had previously secured investments from JiFeng Capital in its Pre-A round financing earlier in January 2025.

Additionally, the National Medical Products Administration (NMPA) approved the Hantong Medical-developed "HawkSonic" Renal Artery Ultrasound Ablation System for entry into a special review procedure to expedite its certification process. This recognition underscores the product's technological advancement and clinical application value, targeting the hypertension patient population.

Industry Overview in China

Hypertension has emerged as the most common chronic illness in China, with over 250 million affected individuals. The latest guidelines indicate hypertension is a major risk factor for cerebrovascular and cardiovascular diseases,